<DOC>
	<DOC>NCT01382992</DOC>
	<brief_summary>EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation detection.For late stage NSCLC, we hypothesis plasma sample is an alternative for detecting EGFR mutations.</brief_summary>
	<brief_title>A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Nonsmall cell lung cancer Available plasma and pathologically confirmed tissue slices(prechemo and preradio therapy) Informed Consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Carcinoma, Non-Small-Cell Lung</keyword>
	<keyword>erbB-1</keyword>
</DOC>